Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Reporting Period: Quarter ended March 31, 2026 (Form 10-Q)
Business Overview: The Company operates as a single segment focused on drug development and the Molecule.ai AI-driven platform for molecular discovery. In November 2025, the Company acquired Molecule.ai assets and simultaneously wound down clinical trials for its lead candidate, Ropidoxuridine. The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,152,471) | $(3,053,007) |
| Net Loss Per Share (Basic & Diluted) | $(0.43) | $(7.60) |
| Cash and Cash Equivalents (End of Period) | $1,089,946 | $4,512,607 |
| Working Capital Deficit | $(5,842,657) | $(7,463,980) |
| Total Assets | $11,809,327 | $10,475,977 |
| Total Liabilities | $8,463,084 | $8,221,531 |
| Stockholders' Equity | $3,346,243 | $3,285,265 |
Cash Flow Summary (Q1 2026):
- Operating Activities: $(2,417,309)
- Investing Activities: $(36,000)
- Financing Activities: $3,209,250 (primarily from equity issuance)
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 29% ($900,536) compared to Q1 2025, driven by a significant reduction in Research and Development (R&D) expenses.
- R&D Expenses: Decreased 83% to $267,240 from $1,573,928, primarily due to the wind-down of Ropidoxuridine clinical trials and reduced subcontractor costs.
- General and Administrative (G&A): Increased 94% to $1,160,556 from $596,886. This increase is attributed to $600,000 in amortization of the Molecule.ai developed technology asset and $100,000 in investor relations marketing costs.
- Other Income: Shifted from a net expense of $(101,766) in Q1 2025 to net income of $64,351 in Q1 2026, largely due to a $76,264 gain on the change in fair value of derivative liabilities.
- Liquidity: Cash balances increased from $334,005 at year-end 2025 to $1,089,946 at March 31, 2026, following a March 2026 equity offering.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. It has a working capital deficit of $5.8 million and expects to continue incurring losses. Future operations depend on successful equity/debt financing and commercialization of the Molecule.ai platform.
- Recent Financing: In March 2026, the Company closed an underwritten public offering raising approximately $3.2 million in net proceeds ($3.5 million gross). $1.25 million of these proceeds were allocated to marketing efforts.
- Subsequent Events (Merger): On April 30, 2026, the Company entered into a Merger Agreement with United Dogecoin Inc., which closed on May 6, 2026. The transaction involved the issuance of Series B-1 Preferred Stock and a PIPE financing of $9.55 million in Series B-2 Preferred Stock and warrants.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2026, citing material weaknesses in accounting transaction processing, IT general controls, and entity-level controls.
- Contingent Consideration: The Company has accrued $2,000,000 in contingent consideration for Molecule.ai milestones, which are deemed probable of achievement.
Investor Verification Checklist
- Merger Completion: Verify the final terms and shareholder approval status of the May 6, 2026 merger with United Dogecoin Inc. and the subsequent capital structure.
- Liquidity Runway: Assess the sufficiency of the $1.1 million cash balance against the $5.8 million working capital deficit and upcoming milestone payments for Molecule.ai.
- Internal Control Remediation: Review the timeline and progress of remediation efforts for the identified material weaknesses in financial reporting controls.
- Molecule.ai Commercialization: Evaluate the progress of the Molecule.ai platform in generating revenue to offset the high amortization costs ($632k in Q1 2026).
- Legal Proceedings: Monitor the status of the dispute with Boustead regarding the Right of First Refusal (ROFR), though no accrual was made as of the filing date.